Page 144 - CW E-Magazine (12-12-2023)

Pharmaceuticals

FORMULATIONS
Akums Drugs acquires new tablet manufacturing

facility in Baddi

Akums Drugs and Pharmaceuticals “Once operational, the Baddi
Ltd., a contract manufacturing pharma- facility will play a signifi cant role in
ceutical company, has announced the augmenting our manufacturing capa-
acquisition of a new formulation faci- bilities, allowing us to effi ciently
lity in Baddi, Himachal Pradesh. This address the needs of our clients,” said
facility, the 12th under Akums and the Mr. Sanjeev Jain, Joint Managing
second in Baddi, will enhance the com- Director, Akums.
pany’s tablet manufacturing capacity,
as per the release. Akums has a network of manufac-
turing facilities for numerous dosage
The newly acquired facility, spread forms in various therapeutic segments.
across approximately 6 acres, is cur- The company is also planning to launch
rently being upgraded and is likely to its initial public offering (IPO) next
be operational in 2024. year.

BIOPHARMACEUTICALS
Sun Pharma subsidiary seals licensing agreement

with Aclaris Therapeutics

Sun Pharmaceutical Industries has Under the terms of the agreement, The exclusive license is intended
entered into a licensing agreement Aclaris has exclusively granted Sun for the treatment of alopecia areata (AA)
with Aclaris Therapeutics, Inc., a clini- Pharma the rights to specifi c patents for or androgenetic alopecia (AGA). It
cal-stage biopharmaceutical company utilising deuruxolitinib, Sun Pharma’s involves an initial payment of $15-mn,
specialising in the development of JAK inhibitor, or other isotopic forms along with subsequent regulatory and
innovative drugs for immuno-infl am- of ruxolitinib, the company noted in its commercial milestones, as well as
matory diseases. exchange fi ling. royalties.
Zydus receives USFDA nod for methylene blue

injection in vials

Zydus Lifesciences Ltd. has The majority of current market
received fi nal approval from the USFDA usage is still on the ampoule presenta-
for the manufacturing and marketing tion, whereas Zydus is offering a generic
of Methylene Blue Injection, available version in vials. According to the com-
in 10-mg/2-ml and 50-mg/5-ml variants. pany, a vial presentation is an afforda-
ble option for hospitals with signifi cant
The drug is the generic equivalent benefi ts and advantages. It has no risk
of the Reference Listed Drug (RLD), of glass particulate contamination like
ProvayBlue Injection, and is used for The product had an annual sale of in ampoules and provides various bene-
treating paediatric and adult patients approximately $73.4-mn in the US as fi ts like ease of use, handling and fl exi-
with acquired methemoglobinemia. of October 2023, Zydus said. ble options with reduced dose waste.

144 Chemical Weekly December 12, 2023

Contents Index to Advertisers Index to Products Advertised